---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-017821"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2026-05-19T21:26:35+00:00"
generated_at: "2026-05-19T21:30:38.673874+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Monopar announces Phase 2 publication: ALXN1840 improves copper balance in Wilson disease

## Summary
- Cumulative mean decrease in copper balance of -6.08 mg over 21 days (95% CI: -10.18 to -1.98 mg).
- Mean daily change of -0.37 mg (p=0.005) on 15 mg/day dosing; -0.29 mg (p=0.023) overall.
- ~50% increase in fecal copper output-to-intake ratio vs baseline (p=0.041).
- ALXN1840 well tolerated; no serious adverse events reported in the single-arm Phase 2 trial.
- Improvements seen even in patients with mean 16 years prior standard-of-care treatment.

## SEC filing metadata
- accession: 0001437749-26-017821
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2026-05-19T21:26:35+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774926017821/0001437749-26-017821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774926017821/mnpr20260513_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-017821
- JSON: https://secwatch.observer/filing/0001437749-26-017821.json
- Plain text: https://secwatch.observer/filing/0001437749-26-017821.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.